Nahoko Kaniwa, Emiko Sugiyama, Yoshiro Saito, Kouichi Kurose, Keiko Maekawa, Ryuichi Hasegawa, Hirokazu Furuya, Hiroko Ikeda, Yukitoshi Takahashi, Masaaki Muramatsu, Masahiro Tohkin, Takeshi Ozeki, Taisei Mushiroda, Michiaki Kubo, Naoyuki Kamatani, Masamichi Abe, Akiko Yagami, Mayumi Ueta, Chie Sotozono, Shigeru Kinoshita, Zenro Ikezawa, Kayoko Matsunaga, Michiko Aihara
Pharmacogenomics 14(15) 1821-31 2013年11月 査読有り
AIM: This preliminary study investigated genomic biomarkers for Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN), related to three antiepileptic drugs, zonisamide, phenobarbital and phenytoin. PATIENTS & METHODS: HLA class I and HLA-DRB1 loci were genotyped for Japanese patients with zonisamide-, phenobarbital- or phenytoin-induced SJS/TEN (n = 12, 8 and 9, respectively) and for healthy Japanese volunteers (n = 2878). RESULTS: Carrier frequencies of HLA-A*02:07 in patients with zonisamide-induced SJS/TEN and in the general Japanese population were 41.7 and 6.81%, respectively. Carrier frequencies of HLA-B*51:01 in patients with phenobarbital- and phenytoin-induced SJS/TEN and in controls were 75.0, 55.6 and 15.2%, respectively. HLA-A*02:07 and HLA-B*51:01, in a dominant model, were significantly associated with zonisamide- and phenobarbital-induced SJS/TEN, respectively (Pc = 0.0176 and 0.0042, respectively). CONCLUSION: Our data suggest that HLA-A*02:07 and HLA-B*51:01 are potential biomarkers for zonisamide- and phenobarbital-induced SJS/TEN, respectively, in Japanese individuals.